Aignostics raised $34 million in a Series B funding round led by ATHOS to enhance precision medicine with AI through new product offerings and US expansion.
HtgfMayo ClinicWellington PartnersBoehringer Ingelheim Venture FundCarma FundVc Fonds Technologie Managed By Ibb VenturesAthos
Description
Aignostics announced it has raised $34 million in Series B financing to support new product offerings, US expansion, and development of pathology foundation models. The round was led by ATHOS, with investments from Mayo Clinic and other existing investors.
Who to call at Aignostics, and when
A new round usually means Aignostics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Aignostics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Aignostics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Aignostics. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Aignostics
Location
Berlin, Berlin, Germany
About
Aignostics is an artificial intelligence (AI) company that transforms complex multimodal pathology data into valuable insights. By leveraging proprietary multimodal clinical data and rigorous scientific methods, Aignostics develops innovative products and services for precision medicine. The company collaborates with biopharmaceutical partners to support drug discovery and development. Established in 2018 as a spin-off from Charité Berlin, Aignostics has garnered significant investment and operates in Berlin and New York.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Aignostics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BerlinBiotechnologyHealth CareArtificial IntelligenceMachine LearningHealth Diagnostics